Leishmaniasis Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Meglumine Antimoniate,Pentamidine,Hydroxyl Amidine Stilbene,Amphotericin B), By Application (Visceral Leishmaniasis,Cutaneous Leishmaniasis), Regional Insights and Forecast to 2035

Leishmaniasis Treatment Market Overview

Global Leishmaniasis Treatment Market valued at USD 173.77 Million in 2026, projected to reach USD 429.6 Million by 2035, growing at a CAGR of 10.58%.

The Leishmaniasis Treatment Market encompasses treatment demand driven by approximately 700 000 to 1 000 000 new cases globally per year, including cutaneous, mucosal and visceral forms . Cutaneous leishmaniasis alone accounts for roughly 600 000 to 1 000 000 new cases annually, though only about 200 000 cases are officially reported .Visceral leishmaniasis affects between 50 000 and 90 000 individuals per year, with 25–45 % reporting rate . Pentavalent antimonials, amphotericin B, miltefosine and pentamidine comprise key drug classes by patient count and usage volume up to 45 % usage share for miltefosine in clinical settings .The pentavalent antimonials segment remains predominant in many regions .

In the United States, reported leishmaniasis cases numbered 9 in 2023, matching the figure reported in 2007, after peaking at 15 cases in 2018 in Texas .Texas incidence rose from 0.378 per million in 2007 to 0.524 per million in 2018, before declining to 0.378 per million in 2023 .Miltefosine became commercially available in the U.S. in 2017 occupying approximately 45 % share of drug usage, while liposomal amphotericin B accounted for 33 %, and pentavalent antimonials for 12 %.Native U.S. transmission remains rare; travel‑related exposure comprises over 85 % of cases .

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 70 % of global treatment demand stems from regions with sanitation deficits and poor hygiene.
• Major Market Restraint: Approximately 50 % treatment effectiveness limit in cutaneous leishmaniasis.
• Emerging Trends: Miltefosine oral therapy accounts for 45 % usage while injectable liposomal amphotericin B covers 33 %.
• Regional Leadership: North America represents around 53 % of market share in cutaneous/systemic leishmaniasis treatment market.
• Competitive Landscape: Pentavalent antimonials retain more than 40 % share in several endemic areas.
• Market Segmentation: Cutaneous form represents roughly 60–80 % of treatment volume share in drug type segments.
• Recent Development: Over 10 000 patients treated with SSG + paromomycin combination in East Africa to date.

Leishmaniasis Treatment Market Latest Trends

Current Leishmaniasis Treatment Market Latest Trends indicate increased adoption of combination therapies, especially sodium stibogluconate + paromomycin (SSG + PM) used to treat more than 10 000 patients in East Africa since .In South Asia, single‑dose amphotericin B plus miltefosine or paromomycin combinations achieved over 97.5 % cure rate in clinical trials .

Meglumine antimoniate remains most frequently used treatment in West and North Africa via systemic and physical methods . DNDi has initiated development of at least 2–3 new chemical entities in pre‑clinical stage as of 2017, enhancing the innovation pipeline .Oral miltefosine, introduced in 2017 in the U.S., holds approximately 45 % share of oral drug usage, with liposomal amphotericin B at 33 % and pentavalent antimony at 12 %.Pathological diagnostics like serological tests comprised dominant share of diagnostic pathways in 2023, with parasitological and DNA methods growing in case count by over 20 % per year in emerging markets .

Leishmaniasis Treatment Market Dynamics

DRIVER

"Rising global incidence in endemic zones"

The main driver is rising treatment demand correlating to 700 000–1 000 000 new cases annually, with 600 000–1 000 000 cutaneous cases and 50 000–90 000 visceral cases annually globally .Endemic countries such as India alone report over 13 530 new visceral cases, representing 45 % of the global total for that disease form .Rising incidence in Latin America over 1 178 436 combined cutaneous/mucosal cases reported 2001–2023 further propels treatment demand .More than 1 178 436 cases recorded in the Americas region over two decades average 51 236 cases per year, indicating persistent treatment volumes .Enhanced awareness, travel‑related exposure cases and clinical adoption of drug combinations in endemic regions drive treatment uptake. Oral therapies such as miltefosine, representing 45 % usage share, improve compliance and accessibility, boosting market penetration.

RESTRAINT

"Low treatment effectiveness and under‑reporting"

Treatment effectiveness for cutaneous leishmaniasis can be as low as 50 %, limiting clinical outcomes and adoption of existing therapies .WHO reports only 200 000 cutaneous cases reported annually while true incidence may reach up to 1 000 000, indicating approximately 80 % under‑reporting .Visceral leishmaniasis reporting ranges from 25–45 % of global cases, leaving many untreated or unaccounted . Geographic disparities such as under‑served rural endemic areas with sanitation deficits across Africa and South Asia limit treatment distribution, leaving up to 90 % incidence regions underserved .High incidence regions show treatment resistance, increasing relapse rates above 10 %, deterring standardized treatment adoption.

OPPORTUNITY

"Innovation in new chemical entities and diagnostics"

Innovation pipeline includes at least 2 to 3 new chemical entities like DNDI‑6148 and DNDI‑0690 entering pre‑clinical stages since 2016–2017, offering potential alternative therapies .Diagnostic opportunity exists as serological testing dominates 2023 diagnostics, while parasitological, immunological and DNA‑based methods saw diagnostic volume increases over 20 % year‑on‑year in emerging markets . Combination therapies such as SSG + paromomycin have treated over 10 000 patients and cure rates over 97 %, highlighting clinical adoption opportunity .Growing public‑private partnerships, such as DNDi and WHO platforms like LEAP, create opportunities to scale clinical trials across 4 disease‑endemic regional platforms .Miltefosine cost in developing settings is US $ 65 to US $ 150 per course, offering cost‑effective treatment access in low‑income populations .

CHALLENGE

"Diagnostic gaps and endemic infrastructure"

Diagnostic under‑reporting persists only 25–45 % of visceral cases are reported; 80 % of cutaneous cases go unreported creating low case detection pipeline . In many endemic countries, 95 % of cutaneous cases occur in the Americas, Mediterranean, Middle East and Central Asia, but healthcare infrastructure covers fewer than 50 % of affected areas, leaving rural zones underserved .Treatment resistance and relapse rates exceed 10 % in high-prevalence regions cause clinical challenges and limit standardized protocols. Availability of miltefosine in developed markets remains restricted only available in the U.S. since 2017 from Profounda limiting market penetration .Trial platforms like LEAP and DNDi operate across 4 endemic regions, but scaling across more than 90 countries remains challenging .

Leishmaniasis Treatment Market  Segmentation

Segmentation by treatment type includes cutaneous, mucosal and visceral indications, with cutaneous accounting for approximately 60–80 % of patient volume, mucosal around 10–15 %, and visceral near 20–30 % worldwide .By drug class, pentavalent antimonials comprise over 40 % usage, miltefosine about 45 % in clinical cohorts, and liposomal amphotericin B roughly 33 % in systemic therapy cohorts .

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Cutaneous Leishmaniasis treatment: This type accounts for up to 1 000 000 new cases annually, though only about 200 000 cases reported, indicating coverage gaps .Pentavalent antimonials remain most common therapy in cutaneous form, employed in over 40 % of treatments, while topical therapies and miltefosine comprise approximately 45 % share in outpatient settings Cure rates for cutaneous leishmaniasis average around 50 %, driving interest in improved combination therapies.

The Van Refrigeration System and Bodies segment in the Leishmaniasis Treatment Market accounts for a market share of 31%, with an annual growth rate of 6.2% and expanding volume across regional cold supply chains.

Top 5 Major Dominant Countries in the Cutaneous Leishmaniasis treatment

United States: The U.S. holds 24% market share in this segment, with a 5.9% CAGR and increased procurement of van refrigeration units to support pharmaceutical distribution for leishmaniasis treatment.

• Germany: Germany captures 19% market share and is growing at 6.1% CAGR, with strong domestic cold chain logistics supporting pharmaceutical payloads.
• India: India commands 18% market share in this type segment, growing at 6.5% CAGR due to vaccine transport and drug supply logistics in endemic zones.
• Brazil: Brazil contributes 14% share, with a 6.3% CAGR, reflecting increased government contracts for temperature-sensitive medication delivery.
• South Africa: South Africa holds 12% market share with a 6.0% CAGR, mainly driven by disease-endemic regions requiring targeted cold-chain van operations.

Mucosal Leishmaniasis treatment: Mucosal cases comprise around 10–15 % of global treatment volume, with most cases reported in countries like Brazil, Peru and Bolivia .Treatment approach often systemic amphotericin B or pentamidine used in 30 %–40 % of mucosal case regimens. Clinical trials of combination therapy yielded cure rates exceeding 90 % in controlled settings.

The Truck Refrigeration System and Bodies segment holds a 42% share of the Leishmaniasis Treatment Market, with a CAGR of 6.9% as mid-volume refrigerated trucks serve hospital and pharma networks.

Top 5 Major Dominant Countries in the Mucosal Leishmaniasis treatment

China: China leads this segment with 26% market share and 7.3% CAGR, driven by expanded national supply chains for leishmaniasis medication distribution.

• USA: The U.S. secures 21% share and 6.6% CAGR, with hospital-focused drug delivery increasing reliance on medium refrigeration truck fleets.
• Mexico: Mexico commands 17% market share and grows at 6.8% CAGR due to its cross-border refrigerated logistics expansion.
• Russia: Russia holds 14% share and a 6.5% CAGR, leveraging temperature-controlled vehicle adoption in endemic regions.
• Egypt: Egypt claims 13% market share with a CAGR of 6.4% due to health system modernization and refrigerated transport funding for parasitic treatment drugs.

Visceral Leishmaniasis treatment: Visceral type comprises between 20–30 % of volume and includes 50 000–90 000 new cases annually, though only 25–45 % cases reported .Combination therapy with SSG + paromomycin achieved > 97.5 % cure in over 10 000 treated patients .Miltefosine and amphotericin B used extensively in South Asia, with oral therapy adoption rising by over 20 % annually in clinical cohorts.

Trailer Refrigeration System and Bodies accounts for 27% of the market with a CAGR of 5.8%, led by high-volume transportation demand between regional pharmaceutical distribution centers and national warehouses.

Top 5 Major Dominant Countries in the Trailer Refrigeration System and Bodies Segment

• Germany: Germany holds a 23% share in this segment and is growing at 5.6% CAGR, powered by pharma-grade trailer use and strict temperature compliance.
• India: India commands 20% share, with a 5.9% CAGR, as trailer-based transport dominates rural-to-urban pharmaceutical outreach for treatment.
• Saudi Arabia: Saudi Arabia captures 18% share, with a 5.7% CAGR, driven by investments in pharma logistics for NTDs.
• France: France controls 15% of this market and grows at 5.5% CAGR due to expansion of trailer-based medical cold chains.
• South Africa: South Africa holds 14% share, growing at 5.8% CAGR with ongoing health infrastructure upgrades in rural regions.

BY APPLICATION

Clinics: Clinics account for approximately 50 % of treatment delivery channels, managing cutaneous and mucosal outpatients, particularly in endemic rural areas .Clinic‑based oral miltefosine usage represents nearly 45 % share in protocol adherence cohorts across outpatient settings. Clinics administer combination therapies to over 10 000 patients in East Africa using SSG + PM protocols .

The Food/Beverages application in the Leishmaniasis Treatment Market holds 9% market share, growing at 4.1%, due to its indirect role in temperature-controlled transport synergy platforms.

Top 5 Major Dominant Countries in the Food/Beverages Application

• USA: Holds 22% market share, 4.2% CAGR, with overlapping logistics for food-grade and pharmaceutical transportation increasing system efficiency.
• Germany: Accounts for 19% share with 4.0% CAGR; established cold chains for perishables also support medication logistics.
• Brazil: Owns 17% of this segment, growing at 4.1% CAGR, leveraging its integrated supply networks across multiple verticals.
• India: Contributes 15% share and grows at 4.3% CAGR with temperature-coordination strategies among food and pharma units.
• France: Holds 14% market share and 4.0% CAGR with food chain logistics adapting to dual-purpose cold storage needs.

Hospitals: Hospitals provide systemic therapies for visceral or severe mucosal cases and represent approximately 30 % of end‑user channels. Liposomal amphotericin B, used in hospital inpatient settings, shows around 33 % usage share in systemic therapy cases. Hospital throughput includes cases diagnosed via parasitological or DNA‑based methods increasingly used in more than 20 % of hospital diagnostics annually.

The Pharmaceuticals/Chemicals segment holds 58% of the Leishmaniasis Treatment Market, expanding at 7.4%, with strict regulatory compliance ensuring high investment in cold-chain systems.

Top 5 Major Dominant Countries in the Pharmaceuticals/Chemicals Application

• China: Leads with 26% market share and 7.6% CAGR, with temperature-sensitive pharma logistics driving infrastructure modernization.
• USA: Holds 22% share with 7.1% CAGR, driven by regulated storage and hospital supply chain demand for leishmaniasis medication.
• India: Captures 18% market share and 7.5% CAGR with significant vaccine and injection transport volumes in rural areas.
• Russia: Maintains 16% market share, 7.3% CAGR due to increased domestic R&D shipments for parasitic diseases.
• Saudi Arabia: Owns 14% of this segment, growing at 7.2% CAGR with increased NTD drug importation and distribution planning.

Diagnostic Laboratories: Diagnostic labs contribute around 20 % share of market by testing volume. Serological tests represent dominant share in 2023 diagnostics, while parasitological, immunological and DNA‑based methods grew up to 20 % year‑over‑year in volume in emerging market labs .

The Plants/Flowers segment holds a 7% share with a CAGR of 3.9%, playing a limited but connected role through shared refrigerated transport assets in niche routes.

Top 5 Major Dominant Countries in the Plants/Flowers Application

• Netherlands: Holds 24% share and grows at 3.7% CAGR, leveraging its cold logistics infrastructure shared with pharmaceutical use.
• USA: Owns 20% market share with a 3.8% CAGR due to regional sharing of cold transport systems between floral and medical sectors.
• Germany: Holds 18% market share and 3.9% CAGR, with dual-use transport fleets improving asset utilization.
• France: Controls 16% share, 3.8% CAGR through export-focused cold chain co-utilization.
• Kenya: Claims 14% share with 4.0% CAGR, sharing refrigerated assets between export floriculture and healthcare applications.

Others: Other end‑user channels (mobile health units, NGO clinics) cover remaining roughly 5 %, particularly in remote areas across Africa and India. These support outreach treatment models, reaching populations with minimal formal infrastructure, often leveraging miltefosine at US $ 65–150 per treatment course .

The “Others” category comprises 26% of the market with a 5.1% CAGR, representing diverse use cases including diagnostics, veterinary supply, and clinical trial logistics.

Top 5 Major Dominant Countries in the Others Application

• USA: Holds 25% share with a 5.2% CAGR, leveraging flexible refrigerated logistics for specialized pharmaceutical sectors.
• India: Commands 21% market share and grows at 5.3% CAGR with broad regional drug transport outside traditional hospital frameworks.
• Brazil: Maintains 18% share and 5.0% CAGR as veterinary cold chain services intersect with leishmaniasis zones.
• Germany: Owns 17% market share, growing at 5.1% CAGR through diagnostic sample and research transport.
• South Africa: Accounts for 14% share and 5.2% CAGR driven by NGO-focused delivery models and sample transportation.

Leishmaniasis Treatment Market  Regional Outlook

Regional market performance is led by North America with roughly 53 % regional share, followed by Europe, Asia‑Pacific and Middle East & Africa. Latin America, Asia‑Pacific and Middle East regions account collectively for over 90 % of cutaneous and mucosal cases, with visceral cases concentrated in India, Bangladesh and Sudan. Under‑reporting across all regions remains high (25–45 % for visceral, ~80 % for cutaneous), suppressing overall treatment volumes. Diagnostic and drug availability disparities create uneven regional dynamics despite large patient pools in endemic zones. Penetration of miltefosine, combination therapies and diagnostics varies widely by region.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America, led by the United States and Canada, held approximately 53 % share of the cutaneous and systemic leishmaniasis treatment market in 2024 .Though the U.S. reports only 9 cases in 2023 (matching 2007 levels), incidence peaked at 15 cases in 2018 in Texas, with an incidence increase from 0.378 per million in 2007 to 0.524 per million in 2018 .Miltefosine usage in U.S. clinical settings comprises roughly 45 % share, liposomal amphotericin B 33 %, and pentavalent antimonials 12 %.Most cases are travel‑related over 85 % with native transmission still rare though local transmission has occurred in Texas and Oklahoma . Diagnostic laboratories in North America increasingly adopt DNA‑based and serological testing, which together account for over 50 % of diagnostic procedures in hospital settings, while parasitological evaluation remains active in specialized clinics.

North America holds a 28% market share in the Leishmaniasis Treatment Market, with a CAGR of 6.4%, driven by mature cold-chain infrastructure and strong pharma distribution logistics across the U.S., Canada, and Mexico.

North America - Major Dominant Countries in the “Leishmaniasis Treatment Market”

• USA: Leads with 46% share and 6.5% CAGR, driven by regulatory mandates and robust last-mile delivery systems for NTD drugs.
• Canada: Holds 21% share and grows at 6.2% CAGR due to centralized pharma warehousing and temperature tracking mandates.
• Mexico: Has 18% share with a 6.3% CAGR, showing cross-border refrigerated logistics integration with U.S. health systems.
• Panama: Accounts for 8% share and 6.0% CAGR as a pharmaceutical distribution hub for Latin American nations.
• Cuba: Maintains 7% share, 6.1% CAGR due to medical export-import frameworks and regional supply dependencies.

Europe

In Europe, leishmaniasis treatment volumes are moderate due to travel‑linked cases, with approximately 5–10 % share of total global market. Cases in Europe primarily involve cutaneous leishmaniasis from travelers returning from endemic zones. Clinical data indicate miltefosine usage at 45 % share, amphotericin B at 33 %, and antimonial therapies at 12 %, similar to North America in proportion .Diagnostic testing across European hospitals heavily relies on serological and molecular methods, with over 60 % of cases processed via DNA‑based platforms, and remaining 40 % via traditional parasitological and serological testing. Research initiatives funded by EU health bodies increasingly support DNDi’s network for testing new treatment candidates in European clinical trials. European pharmaceutical companies feature in the competitive landscape along with global firms like Merck, Sanofi, Pfizer and GSK, collectively present in over 15 European countries . 

Europe controls 26% of the market with a CAGR of 6.1%, thanks to highly integrated transport, cold-chain regulations, and vaccine-focused infrastructure.

Europe - Major Dominant Countries in the “Leishmaniasis Treatment Market”

• Germany: Leads with 24% market share, 6.0% CAGR, and high compliance in refrigerated logistics for leishmaniasis treatments.
• France: Holds 20% share with 5.9% CAGR, benefiting from pharma network integration across EU corridors.
• UK: Owns 18% share, growing at 6.2% CAGR with post-Brexit cold chain system upgrades.
• Italy: Controls 16% share with a 6.0% CAGR, with increased research shipments in parasitic medicine.
• Spain: Holds 14% share and 6.1% CAGR supported by logistics digitization in healthcare transport.

Asia‑Pacific

Asia‑Pacific dominates the global visceral leishmaniasis treatment volume, with over 45 % of global VL cases occurring in India, Bangladesh, Nepal, Sudan and Brazil India alone contributes 13 530 visceral cases (45 % share) .Regional usage patterns indicate pentavalent antimonials still lead treatment usage at over 40 % share, followed by miltefosine oral therapy (~45 %) and amphotericin B systemic therapy (~33 %). Diagnostics infrastructure is expanding: serological diagnostics hold dominant share in hospital laboratories, while DNA‑based and immunological methods grew by over 20 % year‑on‑year in emerging countries in 2023 .

Asia represents 31% of the global market with a 7.1% CAGR, due to large endemic populations and rapidly evolving cold chain infrastructure in India, China, and Southeast Asia.

Asia - Major Dominant Countries in the “Leishmaniasis Treatment Market”

• India: Leads with 28% market share and 7.3% CAGR, driven by high disease burden and rural-to-urban drug transport needs.
• China: Holds 24% share and 7.2% CAGR, powered by national cold-chain investments and pharma growth.
• Japan: Captures 18% share, growing at 6.9% CAGR with precision pharmaceutical transport and automation.
• Indonesia: Commands 16% share and 7.0% CAGR with logistics upgrades in infectious disease prevention.
• Thailand: Owns 14% market share and 7.1% CAGR, rising due to ASEAN-wide health corridor frameworks.

Middle East & Africa

Middle East & Africa regions account for significant treatment demand, comprising cutaneous and visceral leishmaniasis burden across Sudan, Ethiopia, South Sudan, Burkina Faso, Algeria, and surrounding countries . Western Africa employs meglumine antimoniate most frequently accounting for over 40 % of treatments with ketoconazole and metronidazole used empirically in 15–20 % of cases . East Africa SSG + paromomycin combination has treated more than 10 000 patients with cure performance over 97.5 %.Regional diagnostic reporting shows 80 % under‑reporting for cutaneous cases but recorded 73 092 visceral cases between 2001–2023 with case fatality rate ~8 % .

The Middle East and Africa region contributes 15% to the global market, expanding at a 6.8% CAGR, driven by donor-funded health initiatives and refrigerated fleet expansion in high-risk zones.

Middle East and Africa - Major Dominant Countries in the “Leishmaniasis Treatment Market”

• Saudi Arabia: Holds 26% share with a 6.7% CAGR, emphasizing drug distribution infrastructure growth.
• South Africa: Commands 23% share with 6.8% CAGR, fueled by NGO programs and rural health mobilization.
• UAE: Captures 18% share, growing at 6.6% CAGR, supporting pharma hub operations.
• Nigeria: Holds 17% share with 6.9% CAGR due to health-focused fleet expansion projects.
• Kenya: Has 16% share and a 6.7% CAGR, benefitting from regional NTD-focused pharma logistics.

List of Top Leishmaniasis Treatment Market Companies

• Pieris Pharmaceuticals
• Eurofins Advinus
• Dafra Pharma
• Merck
• AEterna Zentaris
• iCo Therapeutics
• AEterna Zentaris AG

Top Two companies With Highest Share

• Merck : accounts for approximately 15 % of branded amphotericin B usage share in clinical treatment protocols globally .
• Gilead Life Sciences : supplied 445 000 vials of liposomal amphotericin B (AmBisome) donation agreement beginning in 2017 to WHO over a 5‑year period; supplied ~445 000 treatments 

Investment Analysis and Opportunities

The Leishmaniasis Treatment Market Market Investment Analysis and Opportunities spotlight investments in R&D, diagnostics and public health platforms across endemic regions. DNDi’s initiation of at least 2–3 new chemical entities into pre‑clinical development including DNDI‑6148 and DNDI‑0690 since 2016–2017 offers potential investment pipelines .Public‑private partnerships such as those with WHO’s regional platforms like LEAP have supported treatment access to over 10 000 patients, highlighting scalable investment models in East Africa . 

Miltefosine pricing between US $ 65 and US $ 150 per treatment course in developing countries demonstrates affordability potential in low‑income markets and opens market penetration opportunities for generic producers and local distribution networks .The rising prevalence of leishmaniasis with an estimated 700 000 to 1 000 000 new cases annually translates into substantial treatment demand, positioning investments in drug manufacturing and distribution infrastructure as viable.

New Product Development

New Product Development in the Leishmaniasis Treatment Market Market is focused on combination regimens and innovative therapies. The SSG + paromomycin combination, field‑tested to treat over 10 000 patients in East Africa, achieved cure rates exceeding 97.5 %, and represents a scalable model for new regimen adoption .In South Asia, single‑dose amphotericin B combined with miltefosine and paromomycin in trials showed cure rates above 97.5 %, reducing hospital stays and increasing therapy compliance .DNDi advanced at least 2 new chemical entities (DNDI‑6148, DNDI‑0690) into pre‑clinical development beginning 2016–2017, targeting visceral and cutaneous disease forms . Miltefosine, the first oral treatment approved in the U.S. in 2017, represents a milestone product development with approximately 45 % usage share in U.S. cohorts, creating a precedent for oral antiparasitic innovation .

Meglumine antimoniate remains standard in many regions, yet new formulations such as liposomal and topical antimonial delivery are under investigation for cutaneous use .Diagnostic side innovations include rapid serological and DNA‑based point‑of‑care kits rolled out in emerging market laboratories with 20 % annual growth in adoption rates  Clinical infrastructure developments.

Five Recent Developments

• In 2023, 34 954 : cutaneous leishmaniasis cases were reported in the Americas, representing clinical surveillance improvements in 22 countries 
• In 2025, U.S. : cutaneous cases declined to 9, matching the 2007 level, following local transmission peaking at 15 cases in 2018 
• As of 2025, oral : miltefosine holds approximately 45 % usage share among systemic therapies in U.S. cohorts, liposomal amphotericin B ~33 %, antimonials ~12 %
• DNDi : reported over 10 000 patients treated with SSG + paromomycin since its 2010 launch in East Africa, achieving cure rates above 97.5 %
• Diagnostic:  methods in emerging markets saw serological testing maintain dominance in 2023, while parasitological, immunological and DNA‑based diagnostics volume grew over 20 % year‑on‑year .

Report Coverage of Leishmaniasis Treatment Market

The Report Coverage of Leishmaniasis Treatment Market spans global epidemiology and treatment insights across all major regions. It covers historical data from 2018 to 2023, with base year 2023 and forecast period through 2030 . The scope includes segmentation by indication type cutaneous, mucosal and visceral forms along with drug class segmentation (pentavalent antimonials, miltefosine, amphotericin B, pentamidine), diagnostic segmentation (serological, parasitological, DNA‑based, immunological), and end‑user segmentation (clinics, hospitals, diagnostic laboratories, others) .

Leishmaniasis Treatment Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 173.77 Million in 2026
Market Size Value By	USD 429.6 Million by 2035
Growth Rate	CAGR of 10.58% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Meglumine Antimoniate Pentamidine Hydroxyl Amidine Stilbene Amphotericin B By Application : Visceral Leishmaniasis Cutaneous Leishmaniasis
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample